Elevance Sues CMS: The Fight Over Medicare Advantage Star Ratings and Calls for Regulatory Consistency

Introduction

The United States healthcare system is complex and deeply influenced by federal regulations governing reimbursement, access, and the overall competitive landscape. Within this system, the Medicare Advantage program and its Star Ratings system have emerged as powerful levers shaping how health insurances compete, how consumers make choices, and ultimately, how care is delivered to millions of older Americans. On July 7, 2026, Elevance Health added another chapter to an ongoing saga over the integrity and transparency of this ratings framework by filing a lawsuit against the Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS). The insurer alleges that CMS unlawfully refused to recalculate its 2026 Medicare Advantage Star Ratings on the same basis that it recently afforded to Clover Health after a court ruling.

In this in-depth exploration, we dissect the factual background, regulatory stakes, industry context, and wider implications of Elevance's legal move. While the headline may focus on a single corporation seeking a favorable outcome, this story raises urgent questions about procedural fairness, regulatory consistency, and the future of a vital element of U.S. healthcare policy. With billions of dollars and tens of millions of beneficiaries hanging in the balance, how this case unfolds could shape the Medicare Advantage landscape for years to come.

The Star Ratings System: A Primer

Medicare Advantage (MA) plans, offered by private insurers under Medicare Part C, are rated by CMS on a five-star system covering quality of care, member experience, and administrative performance. These ratings are not merely symbolic: they directly impact payment bonuses, member enrollment, and marketing privileges for participating health plans. Under the current regulatory framework, achieving high star ratings can translate into significant financial rewards, while lower ratings may mean financial penalties, restrictions, or even market exit for struggling plans.

The formula CMS uses for calculating these star ratings involves a complex mix of quality measures, risk adjustments, and statistical benchmarks. Insurers, as well as public watchdogs and policy experts, have long scrutinized both the inputs and the methodology governing these calculations, with concerns about data accuracy, transparency, and the overall consistency of regulatory application.

Elevance’s Lawsuit: The Key Arguments

According to the MedCity News report, Elevance contends that CMS failed to subject its rating calculations to the same updated methodology that was applied to Clover Health after a court intervened in Clover’s favor. In the Clover case, a federal judge found that CMS had erred in its application of the methodology and subsequently ordered a recalculation. After this ruling, CMS recalculated Clover’s ratings, which had significant financial and competitive consequences.

Elevance, a major national insurer with a substantial Medicare Advantage footprint, argues that by refusing to extend the same recalculation to other insurers facing similar methodological issues, CMS is acting in a way that is both arbitrary and detrimental to fair competition. Elevance’s legal action essentially calls for regulatory parity and consistent application of standards across all plan sponsors.

The merits of Elevance’s case will be determined in federal court, and the company’s specific legal arguments have not been publicly disclosed in their entirety as of this writing. Nevertheless, industry observers are closely watching the proceedings both for their direct impact on Elevance and for what they might mean for the broader MA sector.

The Broader Industry Context: Scrutiny and Confusion

The lawsuit comes at a time of growing tension and confusion within the Medicare Advantage industry. In recent years, stakeholders have raised persistent concerns over:

• Inconsistency in application of methodology: Health plans argue that last-minute or ad-hoc methodological shifts undermine planning and create winners or losers based on regulatory discretion.

• Opaque calculation protocols: While CMS provides guidance on the ratings process, many insurers—and their actuaries—contend that the sheer complexity of the system allows for ambiguity and potential bias.

• Financial stakes: With star ratings dictating billions in bonus payments, even a small variation in performance assessment can have outsize impacts on a plan’s bottom line and market standing.

• Litigation risk: Both the Clover and Elevance cases illustrate the mounting tendency for large payers to use legal avenues as a recourse when regulatory redress fails.

• Implications for beneficiaries: For patients, especially the aging population reliant on Medicare Advantage, changes in plan status tied to ratings can result in shifting benefits, formularies, and provider networks. Legal and regulatory uncertainty trickles down to these individuals, sometimes with little notice or recourse.

Regulatory Consistency: The Heart of the Issue

At the heart of Elevance’s lawsuit is the principle of regulatory consistency. In the context of federal healthcare programs, that means ensuring all participants are governed by the same rules, with processes that are open to scrutiny and recourse. Many policy experts and industry executives see the CMS recalculation framework as a litmus test for whether the agency can administer massive, multi-stakeholder programs according to those principles:

• Legal Uniformity: If a court finds that one plan was disadvantaged by a process error or regulatory misinterpretation, does that establish a precedent for similarly situated organizations? Or is each legal victory confined strictly to its complainant?

• Agency Discretion: How much flexibility do regulators have in interpreting their own rules in real time, especially as new legal interpretations or administrative corrections emerge?

• Competitive Equity: If recalculations fundamentally alter the rankings within a given geography or beneficiary segment, the question arises as to whether affected plans are owed a remedy to preserve a level playing field.

The Potential Impact on the Medicare Advantage Market

If Elevance is successful in court, the implications could be sweeping:

1. Wider Recalculations: CMS might be compelled to review and potentially revise star ratings for a broader set of MA insurers. Such recalculations could realign bonus payments, shift member volumes, and prompt further legal action from affected parties.

2. Heightened Regulatory Scrutiny: Congressional oversight committees and regulatory bodies may intensify their examination of Medicare Advantage administration in light of legal findings, possibly resulting in reforms or new transparency mandates.

3. Market Instability: If the ratings system is seen as unpredictable or subject to ongoing legal uncertainty, health plans may become more conservative in their bids and strategic planning, with implications for innovation and beneficiary options.

4. Beneficiary Uncertainty: For the millions who depend on Medicare Advantage, plan disruptions may translate to changes in healthcare providers, covered medications, or supplemental benefits.

5. Setting New Precedent: The legal outcome might set a national precedent regarding administrative corrections in federal programs, with ripple effects across Medicaid, ACA marketplaces, and other public-private partnership models.

Industry Responses and the Path Forward

The broader healthcare and insurance sectors are watching Elevance's lawsuit closely. Trade associations, policy analysts, and patient advocacy groups are likely to weigh in via amicus briefs or public statements as the case winds its way through the courts.

While regulators have not publicly commented on the specifics of the lawsuit, past agency communications have emphasized the challenge of balancing responsiveness to legal decisions with the need for program stability. As legal cases proliferate, both CMS and HHS face pressure to clarify their protocols, increase communication with plan sponsors, and possibly revisit legislative language underpinning the star ratings system.

Ultimately, the Elevance lawsuit may force a reckoning over whether current rating methodologies can be sufficiently flexible to account for legal precedent while maintaining their foundational integrity. As the story develops, particular attention will be paid to:

• Court timelines and interim rulings
• Motions and statements from both the plaintiff and federal defendants
• Reactions from other large insurers potentially affected by the outcome
• Any immediate impacts to the regulatory schedule for 2026 and subsequent plan years

Conclusion

The Elevance v. CMS case serves as a flashpoint for both the intricacies and the stakes involved in federal healthcare program administration. With so much riding on the perceived fairness and accuracy of regulatory systems like the Medicare Advantage Star Ratings, even a single dispute can send shockwaves through the industry, affecting corporate fortunes, beneficiary choices, and the legislative debate over healthcare policy.

As this lawsuit moves through the federal court system, it may prompt overdue discussions about transparency, uniformity, and accountability in government healthcare programs—a conversation likely to resonate long after the final disposition of the case.

Source: MedCity News – Elevance Sues CMS Over Star Ratings, Seeks Same Recalculation Applied to Clover